huahaipharm(SH:600521)2014-10-15 16:00Financial Performance - Net profit attributable to shareholders was approximately ¥202.40 million, a decrease of 28.87% year-on-year[9]. - Operating revenue for the first nine months reached approximately ¥1.81 billion, an increase of 6.48% compared to the same period last year[9]. - Basic and diluted earnings per share were both ¥0.26, down 27.78% from the previous year[9]. - Total operating revenue for Q3 2023 reached ¥656,175,828.28, a 39.5% increase from ¥470,088,099.52 in Q3 2022[31]. - Net profit for Q3 2023 was ¥74,785,750.09, representing a 16.5% increase compared to ¥64,246,564.30 in Q3 2022[32]. - Total profit for Q3 2023 was ¥85,421,013.54, an increase of 14.5% from ¥74,434,974.65 in Q3 2022[32]. - The company reported a total operating income of ¥1,806,201,008.19 for the first nine months of 2023, up from ¥1,696,263,859.22 in the previous year[31]. - The company’s total comprehensive income for Q3 2023 was ¥74,829,142.88, compared to ¥64,377,852.33 in Q3 2022[32]. Cash Flow - Net cash flow from operating activities was approximately ¥139.21 million, a significant decrease of 66.27% year-on-year[9]. - Cash flow from operating activities for the first nine months of 2023 was ¥1,774,045,156.62, compared to ¥1,738,829,699.86 in the same period last year[41]. - Total cash inflow from operating activities was RMB 1,485,987,217.87, slightly up from RMB 1,477,010,808.98 year-on-year[46]. - Cash outflow from operating activities totaled RMB 1,316,405,348.35, an increase of 17.8% from RMB 1,117,492,700.51 in the previous year[46]. - Investment activities generated a net cash inflow of RMB 342,978,575.43, compared to a net outflow of RMB 493,714,950.53 in the same period last year[47]. - Total cash inflow from financing activities was RMB 1,082,569,647.88, down from RMB 1,941,608,111.00 year-on-year[47]. - Net cash flow from financing activities showed a negative balance of RMB 485,069,479.47, contrasting with a positive RMB 840,202,872.72 in the same period last year[47]. - The ending cash and cash equivalents balance was RMB 396,951,863.88, down from RMB 836,521,682.00 at the end of the previous year[47]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.37 billion, a decrease of 2.19% compared to the end of the previous year[9]. - The total number of shareholders at the end of the reporting period was 29,221[12]. - Total current assets decreased from CNY 2,598,914,177.59 at the beginning of the year to CNY 2,276,109,881.68, a decline of approximately 12.4%[22]. - Total liabilities decreased from CNY 1,446,818,184.52 to CNY 1,150,741,369.48, a reduction of about 20.5%[24]. - Total equity increased from CNY 3,019,285,890.89 to CNY 3,217,443,015.35, reflecting a growth of approximately 6.6%[24]. - The company’s total non-current assets increased from CNY 1,867,189,897.82 to CNY 2,092,074,503.15, reflecting a growth of about 12.0%[23]. - The company’s short-term borrowings increased from CNY 519,878,914.75 to CNY 601,146,165.21, an increase of approximately 15.6%[24]. Investments and Expenditures - The company received government subsidies amounting to approximately ¥10.17 million during the reporting period[10]. - The company reported a loss of approximately ¥1.35 million from non-recurring items for the first nine months[10]. - Investment income surged by 213.21% to ¥26,404,083.86, resulting from higher interest from entrusted loans and financial products[15]. - The company reported a significant increase in long-term equity investments from CNY 350,777,958.51 to CNY 382,845,140.69, an increase of approximately 9.1%[27]. - Development expenditures increased by 67.68% to ¥16,469,006.55, reflecting higher capitalized R&D costs[14]. Impairment and Provisions - The weighted average return on equity decreased by 5.27 percentage points to 6.66%[9]. - The company reported a 441.44% increase in asset impairment losses, totaling ¥9,277,428.10, due to higher bad debt provisions[15]. - The company’s total assets impairment loss for Q3 2023 was ¥176,151.00, compared to a gain of ¥9,693,058.40 in Q3 2022[31].